Skip to Content

Pfizer Inc PFE

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Stewardship

PREMIUM

Good News From BioNTech and Pfizer’s Phase 1/2 COVID-19 Vaccine Trial, but Long Road Ahead

Anna Baran Equity Analyst

Analyst Note

| Anna Baran |

On July 1, partners BioNTech and Pfizer reported positive early data for one of four vaccine candidates against SARS-CoV-2. The data from an ongoing U.S. trial demonstrated promising antibody responses with good safety data for the two lower doses of the vaccine candidate, BNT162b1. We are maintaining our fair values for no-moat BioNTech and wide-moat Pfizer at $40 per ADR and $42.50 per share, respectively.

Read Full Analysis

Company Profile

Business Description

Pfizer is one of the world's largest pharmaceutical firms, with annual sales over $50 billion. Pfizer also spends a leading amount on research and development, close to $8 billion annually. While Pfizer historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, neuroscience drug Lyrica, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor, representing over a fifth of total firm sales.

Contact
235 East 42nd Street
New York, NY, 10017
T +1 212 733-2323
Sector Healthcare
Industry Drug Manufacturers - General
Most Recent Earnings Mar 31, 2020
Fiscal Year End Dec 31, 2020
Stock Type High Yield
Employees 88,300

Related